JP2016533190A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016533190A5 JP2016533190A5 JP2016544736A JP2016544736A JP2016533190A5 JP 2016533190 A5 JP2016533190 A5 JP 2016533190A5 JP 2016544736 A JP2016544736 A JP 2016544736A JP 2016544736 A JP2016544736 A JP 2016544736A JP 2016533190 A5 JP2016533190 A5 JP 2016533190A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid molecule
- nucleotides
- stretch
- nucleotide sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002773 nucleotide Substances 0.000 claims 54
- 125000003729 nucleotide group Chemical group 0.000 claims 54
- 108020004707 nucleic acids Proteins 0.000 claims 30
- 102000039446 nucleic acids Human genes 0.000 claims 30
- 150000007523 nucleic acids Chemical class 0.000 claims 30
- 238000012986 modification Methods 0.000 claims 5
- 230000004048 modification Effects 0.000 claims 5
- 238000000034 method Methods 0.000 claims 4
- 239000007908 nanoemulsion Substances 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 230000035945 sensitivity Effects 0.000 claims 2
- 101000978766 Homo sapiens Neurogenic locus notch homolog protein 1 Proteins 0.000 claims 1
- 239000008346 aqueous phase Substances 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 230000030279 gene silencing Effects 0.000 claims 1
- 102000045609 human NOTCH1 Human genes 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000012071 phase Substances 0.000 claims 1
- 230000001323 posttranslational effect Effects 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13004722.8 | 2013-09-30 | ||
| EP13004722.8A EP2853595A1 (en) | 2013-09-30 | 2013-09-30 | NOTCH 1 specific siRNA molecules |
| PCT/EP2014/002655 WO2015043768A1 (en) | 2013-09-30 | 2014-09-30 | Notch 1 specific sirna molecule |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019133268A Division JP7086039B2 (ja) | 2013-09-30 | 2019-07-19 | ＮＯＴＣＨ １特異的なｓｉＲＮＡ分子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016533190A JP2016533190A (ja) | 2016-10-27 |
| JP2016533190A5 true JP2016533190A5 (enExample) | 2017-11-09 |
| JP6561061B2 JP6561061B2 (ja) | 2019-08-14 |
Family
ID=49304652
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016544736A Expired - Fee Related JP6561061B2 (ja) | 2013-09-30 | 2014-09-30 | ＮＯＴＣＨ １特異的なｓｉＲＮＡ分子 |
| JP2019133268A Active JP7086039B2 (ja) | 2013-09-30 | 2019-07-19 | ＮＯＴＣＨ １特異的なｓｉＲＮＡ分子 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019133268A Active JP7086039B2 (ja) | 2013-09-30 | 2019-07-19 | ＮＯＴＣＨ １特異的なｓｉＲＮＡ分子 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9896690B2 (enExample) |
| EP (2) | EP2853595A1 (enExample) |
| JP (2) | JP6561061B2 (enExample) |
| CN (2) | CN105814202B (enExample) |
| AU (1) | AU2014327809B2 (enExample) |
| CA (1) | CA2924788A1 (enExample) |
| DK (1) | DK3052625T3 (enExample) |
| HR (1) | HRP20211525T1 (enExample) |
| HU (1) | HUE056609T2 (enExample) |
| IL (1) | IL244661B (enExample) |
| LT (1) | LT3052625T (enExample) |
| MX (1) | MX377713B (enExample) |
| RU (1) | RU2651493C2 (enExample) |
| SG (2) | SG10201802593WA (enExample) |
| SI (1) | SI3052625T1 (enExample) |
| WO (1) | WO2015043768A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2853595A1 (en) * | 2013-09-30 | 2015-04-01 | Soluventis GmbH | NOTCH 1 specific siRNA molecules |
| CN115151644B (zh) * | 2019-12-27 | 2024-06-21 | 国立大学法人神户大学 | 癌基因治疗药 |
| CN112626068B (zh) * | 2020-12-21 | 2021-12-03 | 徐州医科大学 | 一种靶向Notch1基因的LncRNA及其应用 |
| CN116790603B (zh) * | 2023-08-18 | 2023-10-31 | 成都中科奥格生物科技有限公司 | 一种sgRNA、CRISPR/Cas9载体及其构建方法和用途 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5378825A (en) | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
| DK1695979T3 (da) | 1991-12-24 | 2011-10-10 | Isis Pharmaceuticals Inc | Gappede modificerede oligonukleotider |
| EP0786522A2 (en) | 1992-07-17 | 1997-07-30 | Ribozyme Pharmaceuticals, Inc. | Enzymatic RNA molecules for treatment of stenotic conditions |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| US5820873A (en) | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
| US5753613A (en) | 1994-09-30 | 1998-05-19 | Inex Pharmaceuticals Corporation | Compositions for the introduction of polyanionic materials into cells |
| US6001311A (en) | 1997-02-05 | 1999-12-14 | Protogene Laboratories, Inc. | Apparatus for diverse chemical synthesis using two-dimensional array |
| US6395713B1 (en) | 1997-07-23 | 2002-05-28 | Ribozyme Pharmaceuticals, Inc. | Compositions for the delivery of negatively charged molecules |
| EP1071753A2 (en) | 1998-04-20 | 2001-01-31 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid molecules with novel chemical compositions capable of modulating gene expression |
| EP1159441B8 (en) | 1999-03-10 | 2008-10-29 | Marie Curie Cancer Care | Delivery of nucleic acids and proteins to cells |
| ES2280826T5 (es) | 2002-08-05 | 2017-08-03 | Silence Therapeutics Gmbh | Nuevas formas adicionales de moléculas de ARN de interferencia |
| CA2565633C (en) | 2004-05-05 | 2016-04-26 | Atugen Ag | Lipids, lipid complexes and use thereof |
| BRPI0906657A2 (pt) * | 2008-01-29 | 2015-07-14 | Proyecto Biomedicina Cima Sl | Métodos e composições capazes de causar um silenciamento pós-transcricional da expressão genética de forma sinérgica |
| CA2717496A1 (en) * | 2008-03-12 | 2009-09-17 | Intradigm Corporation | Compositions comprising notch1 sirna and methods of use thereof |
| EP2123256A1 (en) | 2008-05-19 | 2009-11-25 | Ruhr-Universität Bochum | Perfluorcarbon nanoemulsions with endocytosis enhancing surface for gene-transfer |
| EP2442792A4 (en) * | 2009-06-15 | 2015-12-23 | Alnylam Pharmaceuticals Inc | TESTING GENE PCSK9 LIPID-FORMULATED DSRNA |
| CN103998454A (zh) * | 2011-08-03 | 2014-08-20 | 夸克制药公司 | 用于治疗听力障碍和平衡障碍的双链寡核苷酸化合物 |
| RU2014125496A (ru) * | 2012-01-12 | 2016-02-27 | Кварк Фармасьютикалс, Инк. | Комбинированная терапия для лечения нарушений слуха и равновесия |
| EP2853595A1 (en) * | 2013-09-30 | 2015-04-01 | Soluventis GmbH | NOTCH 1 specific siRNA molecules |
-
2013
- 2013-09-30 EP EP13004722.8A patent/EP2853595A1/en not_active Withdrawn
-
2014
- 2014-09-30 WO PCT/EP2014/002655 patent/WO2015043768A1/en not_active Ceased
- 2014-09-30 JP JP2016544736A patent/JP6561061B2/ja not_active Expired - Fee Related
- 2014-09-30 US US15/026,084 patent/US9896690B2/en active Active
- 2014-09-30 SG SG10201802593WA patent/SG10201802593WA/en unknown
- 2014-09-30 SI SI201431913T patent/SI3052625T1/sl unknown
- 2014-09-30 CN CN201480061599.8A patent/CN105814202B/zh not_active Expired - Fee Related
- 2014-09-30 CN CN202010081100.7A patent/CN111197046A/zh active Pending
- 2014-09-30 HU HUE14777525A patent/HUE056609T2/hu unknown
- 2014-09-30 HR HRP20211525TT patent/HRP20211525T1/hr unknown
- 2014-09-30 RU RU2016116931A patent/RU2651493C2/ru active
- 2014-09-30 EP EP14777525.8A patent/EP3052625B1/en active Active
- 2014-09-30 SG SG11201602437VA patent/SG11201602437VA/en unknown
- 2014-09-30 CA CA2924788A patent/CA2924788A1/en active Pending
- 2014-09-30 DK DK14777525.8T patent/DK3052625T3/da active
- 2014-09-30 MX MX2016004142A patent/MX377713B/es active IP Right Grant
- 2014-09-30 LT LTEPPCT/EP2014/002655T patent/LT3052625T/lt unknown
- 2014-09-30 AU AU2014327809A patent/AU2014327809B2/en not_active Ceased
-
2016
- 2016-03-20 IL IL244661A patent/IL244661B/en unknown
-
2018
- 2018-02-01 US US15/886,386 patent/US10669548B2/en not_active Expired - Fee Related
-
2019
- 2019-07-19 JP JP2019133268A patent/JP7086039B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016074736A5 (enExample) | ||
| JP2017505623A5 (enExample) | ||
| JP2018530530A5 (enExample) | ||
| JP2016116520A5 (enExample) | ||
| CY1119880T1 (el) | Παραγωγα πυρρολοπυριμιδινης για χρηση στη θεραπεια ιικων λοιμωξεων | |
| WO2013074974A3 (en) | Modified rnai agents | |
| HK1219955A1 (zh) | 含4'-硫代修饰的核苷酸的核糖核酸及相关方法 | |
| MX2024005653A (es) | Agentes de acido ribonucleico (arn) de cadena doble modificados. | |
| JP2015519891A5 (enExample) | ||
| JP2018512060A5 (enExample) | ||
| EP4632075A3 (en) | Method for reducing immunogenicity of rna | |
| HK1203075A1 (en) | Substituted phosphorothioate nucleotide analogs | |
| NZ624783A (en) | Modulation of huntingtin expression | |
| JP2010166916A5 (enExample) | ||
| WO2010141511A3 (en) | Polynucleotides for multivalent rna interference, compositions and methods of use thereof | |
| WO2006110688A3 (en) | Rnai therapeutic for respiratory virus infection | |
| JP2014527401A5 (enExample) | ||
| JP2015507625A5 (enExample) | ||
| JP2015128433A5 (enExample) | ||
| WO2012170957A8 (en) | Retinoid-liposomes for enhancing modulation of hsp47 expression | |
| JP2012516856A5 (enExample) | ||
| JP2019506862A5 (enExample) | ||
| JP2015511821A5 (enExample) | ||
| WO2014066915A3 (en) | Methods and compositions to produce ss-rnai activity with enhanced potency | |
| JP2013537404A5 (enExample) |